We purchased shares of Icon in March 2024 for ~$323.00 per share. Why did we sell our ICLR position and move on? Click here ...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY ...
Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback